EUVIMEDΑνακαλύψτε το EUVIMED
ValidierungsstudieOpen access · CC BY 4.0

Impact of IL-8 on survival after TARE in HCC: a comprehensive investigation and external validation from the SORAMIC trial

Aaron Schindler, Janett Fischer, Anne-Bettina Beeskow, Thomas Lincke, Sebastian Ebel, Daniel Seehofer, Timm Denecke, Rhea Veelken, Osama Sabri, Osman Öcal, Max Seidensticker, Thomas Berg and 1 more

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05947-4 ↗

At a glance

Validierungsstudie in Journal of Cancer Research and Clinical Oncology, 2024. Written by Aaron Schindler and 12 co-authors. Institution: Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103, Leipzig, Germany. Major MEDLINE topics: Liver Neoplasms, Carcinoma, Hepatocellular, Interleukin-8. Cited 1 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Universität Leipzig.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Purpose

In the treatment of hepatocellular carcinoma (HCC) with transarterial radioembolization (TARE), identifying reliable biomarkers for predicting survival outcomes remains a critical challenge. We aimed to address this gap by investigating the significance of serum cytokines associated with inflammation as potential biomarkers for the selection of patients for TARE.

Methods

Our retrospective study involved 161 patients diagnosed with HCC who underwent Y90 radioembolization at our medical center between 2010 and 2020. Serum samples from a subset of 78 patients were retrospectively analyzed to determine the concentrations of pro-inflammatory cytokines. The results from the prospective SORAMIC trial were used for independent validation.

Results

With a median overall survival of 36 weeks (range 4-436), our study showed the strongest correlation between 12-week survival and IL-8 levels before treatment ( p < 0.001), while other relevant interleukins, interferon-α2, INF-γ, TNF-α and MCP-1 were not associated with survival. IL-8 levels below the cut-off of 190 pg/mL were significantly associated with increased 12-week and 24-week survival, with hazard ratios of 19.01 (95% CI: 2.29-157.89) and 2.57 (95% CI: 1.05–6.31), respectively ( p = 0.006 and p = 0.039, respectively). In the adjusted multivariate analysis, the 190 pg/mL cut-off for IL-8 remained independently associated with 12- ( p = 0.011) and 24-week survival ( p = 0.039). Similarly, the SORAMIC population showed a strong association between IL-8 levels and 36-week survival ( p = 0.03).

Conclusion

Our study emphasizes the pivotal role of IL-8 as a valuable parameter, demonstrating its potential for predicting treatment outcomes and assessing liver function in patients with HCC undergoing TARE. The robustness of these findings warrants further validation.

Subjects

MeSH terms (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularInterleukin-8HumansFemaleMaleMiddle AgedAgedRetrospective StudiesEmbolization, TherapeuticAdultBiomarkers, TumorAged, 80 and overProspective StudiesPrognosisSurvival Rate

Author keywords

BiomarkersLiver cancerRadiotherapyTranslational research

Substances

Interleukin-8Biomarkers, TumorCXCL8 protein, human

Authors and institutions

  • Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103, Leipzig, Germany.
  • University Liver Tumor Center (ULTC), Leipzig University Medical Center, Leipzig, Germany.
  • Division of Hepatology, Department of Medicine II, Laboratory for Clinical and Experimental Hepatology, Leipzig University Medical Center, Leipzig, Germany.
  • Department of Diagnostic and Interventional Radiology, Leipzig University Medical Center, Leipzig, Germany.
  • Department of Nuclear Medicine, Leipzig University Medical Center, 04103, Leipzig, Germany.
  • Department of Visceral, Thoracic and Vascular Surgery, Leipzig University Medical Center, Leipzig, Germany.

Funding

  • Universität Leipzig

Cite

APA

Schindler, A., Fischer, J., Beeskow, A. B., Lincke, T., Ebel, S., Seehofer, D., Denecke, T., Veelken, R., Sabri, O., Öcal, O., Seidensticker, M., Berg, T., & van Bömmel, F. (2024). Impact of IL-8 on survival after TARE in HCC: a comprehensive investigation and external validation from the SORAMIC trial. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05947-4

Vancouver

Schindler A, Fischer J, Beeskow AB, Lincke T, Ebel S, Seehofer D, et al. Impact of IL-8 on survival after TARE in HCC: a comprehensive investigation and external validation from the SORAMIC trial. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05947-4

BibTeX
@article{Schindler2024,
  author = {Schindler, Aaron and Fischer, Janett and Beeskow, Anne-Bettina and Lincke, Thomas and Ebel, Sebastian and Seehofer, Daniel and Denecke, Timm and Veelken, Rhea and Sabri, Osama and Öcal, Osman and Seidensticker, Max and Berg, Thomas and van Bömmel, Florian},
  title = {Impact of IL-8 on survival after TARE in HCC: a comprehensive investigation and external validation from the SORAMIC trial},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05947-4}
}
Start for free →